All Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers) articles – Page 2

  • shutterstock_2419574549
    Article

    Part two: how ChatGPT enriched animal study results

    2024-07-15T10:00:00Z

    Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.

  • Llm,Large,Language,Models,Concept.,3d,Rendering,Of,An,Artificial
    Article

    Part one: what can scientists do with LLMs today?

    2024-06-24T10:00:00Z

    Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they ...

  • shutterstock_2681386115
    Article

    Kickstarting the use of AI for biotechs: part three

    2024-06-20T10:00:00Z

    Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the third of a three-part series – Dr Raminderpal Singh touches on the decisions that need ...

  • artificial-intelligence-1
    Article

    Kickstarting the use of AI for biotechs: part two

    2024-05-24T10:00:00Z

    Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being ...

  • shutterstock_2539505109
    Article

    Kickstarting the use of AI for biotechs: part one

    2024-05-15T10:00:00Z

    Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining ...